Back to results
US 6,455,678 B1Granted
Human hematopoietic stem and progenitor cell antigen
AssigneeAmCell Corporation
InventorsAmy H. Yin, Sheri Miraglia, Wayne G. Godfry, David W. Buck
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeAmCell Corporation
InventorsAmy H. Yin, Sheri Miraglia, Wayne G. Godfry, David W. Buck
Estimating the term…
A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34bright and contains substantially all of the CFU-GM activity present in the CD34+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
An isolated polypeptide, wherein said polypeptide comprises the amino acid sequence of AC133 as set forth in SEQ ID NO:
An isolated polypeptide, wherein said polypeptide comprises an amino acid sequence wherein said sequence comprises a subsequence of at least 10 amino acids in length of the amino acid sequence of AC133 as set forth in SEQ ID NO:
An isolated polypeptide, wherein said polypeptide comprises the amino acid sequence from extracellular N-terminus, aa 20-107;
Dependencies are inferred from the claim text.